All In Biotech

Free tool

FAERS Monitor: Visipaque 270

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020351 or its brand name (Visipaque 270, Iodixanol). Reports on generic versions are filed under their own applications.

Reports

3,613

Serious

3,321

92% of reports

Hospitalization

1,454

Death reported

273

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus478
  • rash306
  • erythema275
  • dyspnoea257
  • urticaria233
  • nausea180
  • hypotension158
  • vomiting157
  • acute kidney injury143
  • contrast media allergy136
  • anaphylactic reaction128
  • rash maculo-papular120
  • acute generalised exanthematous pustulosis105
  • renal failure acute104
  • swelling face102

Reports by year received

View as table
YearReports
200449
200542
200669
200757
200873
200956
201082
2011136
2012135
2013191
2014282
2015197
2016220
2017200
2018169
2019236
2020170
2021136
2022106
2023201
2024239
2025283
2026284

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,546 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
contrast media allergySignal136466.9393.358,114
acute generalised exanthematous pustulosisSignal10579.866.07,980
rash maculo-papularSignal12031.626.53,506
renal failure acuteSignal10414.311.81,273
anaphylactic reactionSignal12813.511.41,471
swelling faceSignal1029.17.5732
urticariaSignal2338.17.21,454
erythemaSignal2757.87.01,637
pruritusSignal4787.26.72,613
acute kidney injurySignal1435.44.6518
hypotensionSignal1584.63.9444
rashSignal3064.13.7725
dyspnoeaSignal2572.62.3268
vomiting1571.91.773
nausea1801.31.114

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.